Sangui Biotech International (Sangui Biotech International) EBIT : $-0.11 Mil (TTM As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is Sangui Biotech International EBIT?

Sangui Biotech International's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sangui Biotech International's annualized ROC % for the quarter that ended in Mar. 2023 was -11.37%. Sangui Biotech International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -251.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sangui Biotech International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -9.19%.

Sangui Biotech International EBIT Historical Data

The historical data trend for Sangui Biotech International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International EBIT Chart

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

EBIT

Get a 7-Day Free Trial

-0.21

-0.33

-0.18

-0.19

-0.04

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT	Get a 7-Day Free Trial															-0.01	-	0.03	-0.10	-0.03

Competitive Comparison of Sangui Biotech International's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangui Biotech International's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's EV-to-EBIT falls into.

Sangui Biotech International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

Sangui Biotech International (OTCPK:SGBI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sangui Biotech International's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	-0.092 * ( 1 - 0% )	/	( (0.807	+	0.812)	/ 2 )
=	-0.092	/	0.8095
=	-11.37 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.099	-	0.239	-	( 0.009	-	max(0, 0.991	-	0.044	+	0.009	))
=	0.807

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.089	-	0.265	-	( 0.007	-	max(0, 1.027	-	0.039	+	0.007	))
=	0.812

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Sangui Biotech International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Mar. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.132	/	( ( (0.055 + max(-0.221, 0))	+	(0.05 + max(-0.238, 0)) )	/	2 )
=	-0.132	/	( ( 0.055	+	0.05 )	/	2 )
=	-0.132	/	0.0525
=	-251.43 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.014	+	0	+	0.004)	-	(0.239	+	0	+	0)
=	-0.221

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.023	+	0	+	0.004)	-	(0.265	+	0	+	-2.2204460492503E-16)
=	-0.238

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sangui Biotech International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2023 )
	=	-0.105	/	1.142
	=	-9.19 %

Sangui Biotech International EBIT Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines